Fast antibody responses by immuno-targeting and nanotechnology strategies versus HBsAg vaccine

Publish Year: 1400
نوع سند: مقاله ژورنالی
زبان: English
View: 328

This Paper With 6 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJBMS-24-4_017

تاریخ نمایه سازی: 6 اردیبهشت 1400

Abstract:

Objective(s): Though immunization with HBsAg has been routine since the ۱۹۸۰s, it has numerous limitations such as low or none humoral immune responses. Today, nanotechnology is used in vaccinology to achieve higher potency. The present study deals with the achievement of fast antibody response of humoral immune responses using immune-targeting through mannosylated nanocarriers of the vaccine.Materials and Methods: Mannose sugar and HBsAg were attached to the surface of iron oxide nanoparticles. Mannosylated iron oxide nanoparticles conjugated HBsAg (HBsAg +MLCMNP), iron oxide nanoparticles conjugated HBsAg (HBsAg +LCMNP), hepatitis B vaccine, and mere HBsAg were injected twice to BALB/c mice subcutaneously, while suitable control groups were considered. Specific total IgG antibodies were evaluated on the ۷th and ۱۴th days after the final immunization. The avidity maturation of the humoral immune response was assessed with an optimized ELISA. Graph pad prism software was used to analyze statistical data. Results: Results showed that on the seventh day of the final shooting, the mannosylated nano-vaccine caused higher antibody response induction than nano-vaccine without mannose and commercial vaccine groups. After ۱۴ days of the second injection, a significant difference was seen versus the nano-vaccine without mannose but not the commercial vaccine group. In addition, the avidity index in mannosylated nano-vaccine showed a significant increase compared with the nano-vaccine without mannose and mere HBsAg group but not compared with the commercial vaccine.Conclusion: It seems that mannosylated nano-vaccine has more potency to achieve fast antibody responses and also higher quality of humoral immune response.

Authors

Mahsa Rezaei

Department of Biology, Sciences and Research Branch, Islamic Azad University, Tehran, Iran

Seyed Nezamedin Hosseini

Department of Hepatitis B Vaccine Production, Production and Research Complex, Pasteur Institute of Iran, Tehran, Iran

Ramazan Ali Khavari-Nejad

Department of Biology, Sciences and Research Branch, Islamic Azad University, Tehran, Iran

Farhood Najafi

Department of Resin and Additives, Institute for Color Science and Technology, Tehran, Iran

Mehdi Mahdavi

Recombinant Vaccine Research Center, Tehran University of Medical Sciences, Tehran, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • 1. Thirion M, Ochiya T. Roles of micrornas in the ...
  • 2. Nguyen DH, Ludgate L, Hu J. Hepatitis B Virus-Cell ...
  • 3. Liang TJ. Hepatitis B: the virus and disease. Hepatology ...
  • 4. Caccamo G, Saffioti F, Raimondo G. Hepatitis B virus ...
  • 5. Shoaei SD, Sali S, Karamipour M, Riahi E. Non-invasive ...
  • 6. Whitaker JA, Rouphael NG, Edupuganti S, Lai L, Mulligan ...
  • 7. Nashibi R, Alavi SM, Yousefi F, Salmanzadeh S, Moogahi ...
  • 8. Walayat S, Ahmed Z, Martin D, Puli S, Cashman ...
  • 9. Filippelli M, Lionetti E, Gennaro A, Lanzafame A, Arrigo ...
  • 10. Gherardi RK, Eidi H, Crépeaux G, Authier FJ, Cadusseau ...
  • 11. Lindblad EB. Aluminium compounds for use in vaccines. Immunol ...
  • 12. Dezfuli HT, Shahbazzadeh D, Eidi A, Bagheri KP, Pakravan ...
  • 13. Nahar M, Jain NK. Preparation, characterization and evaluation of ...
  • 14. Li X, Wang X, Ito A. Tailoring inorganic nanoadjuvants ...
  • 15. Pusic K, Aguilar Z, McLoughlin J, Kobuch S, Xu ...
  • 16. Zhao Y, Zhao X, Cheng Y, Guo X, Yuan ...
  • 17. Scherer F, Anton M, Schillinger U, Henke J, Bergemann ...
  • 18. Chellat F, Merhi Y, Moreau A, Yahia LH. Therapeutic ...
  • 19. Nahar M, Dutta T, Murugesan S, Asthana A, Mishra ...
  • 20. Sett R, Sarkar K, Das PK. Macrophage-directed delivery of ...
  • 21. Basu MK, Lala S. Macrophage specific drug delivery in ...
  • 22. Hamdy S, Haddadi A, Shayeganpour A, Samuel J, Lavasanifar ...
  • 23. Ghotbi Z, Haddadi A, Hamdy S, Hung RW, Samuel ...
  • 24. Rezaei M, Hosseini SN, Khavari-Nejad RA, Najafi F, Mahdavi ...
  • 25. Siegrist C-A, Pihlgren M, Tougne C, Efler SM, Morris ...
  • 26. Lai RP, Seaman MS, Tonks P, Wegmann F, Seilly ...
  • 27. Xiang SD, Wilson K, Day S, Fuchsberger M, Plebanski ...
  • 28. Thorek DL, Chen AK, Czupryna J, Tsourkas A. Superparamagnetic ...
  • 29. Amstad E, Gillich T, Bilecka I, Textor M, Reimhult ...
  • 30. Qiao R, Yang C, Gao M. Superparamagnetic iron oxide ...
  • 31. Teja AS, Koh P-Y. Synthesis, properties, and applications of ...
  • 32. Pusic K, Aguilar Z, McLoughlin J, Kobuch S, Xu ...
  • 33. Labhasetwar V, Leslie-Pelecky DL. Biomedical applications of nanotechnology: John ...
  • 34. Andrade Â, Ferreira R, Fabris J, Domingues R. Coating ...
  • 35. Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos ...
  • 36. Ezekowitz R, Sastry K, Bailly P, Warner A. Molecular ...
  • 37. Stahl PD, Ezekowitz RAB. The mannose receptor is a ...
  • 38. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau ...
  • 39. Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to ...
  • 40. Steinhagen F, Kinjo T, Bode C, Klinman DM. TLR-based ...
  • 41. Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman ...
  • 42. Mohan T, Verma P, Rao DN. Novel adjuvants & ...
  • 43. Faham A, Altin JG. Antigen-containing liposomes engrafted with flagellin-related ...
  • 44. Sjölander A, Cox JC, Barr IG. ISCOMs: an adjuvant ...
  • 45. Wilkinson BL, Day S, Chapman R, Perrier S, Apostolopoulos ...
  • 46. Nejati S, Mirzaee S, Nouri HR, Farhoudi R, Namvar ...
  • 47. Taylor PR, Martinez-Pomares L, Stacey M, Lin H-H, Brown ...
  • 48. Boscardin SB, Hafalla JC, Masilamani RF, Kamphorst AO, Zebroski ...
  • 49. Goldblatt D, Vaz AR, Miller E. Antibody avidity as ...
  • 50. Wagner DA, Kelly SM, Petersen AC, Peroutka-Bigus N, Darling ...
  • 51. Haughney SL, Ross KA, Boggiatto PM, Wannemuehler MJ, Narasimhan ...
  • نمایش کامل مراجع